Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030552 (paresis)
 5,831 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Recently, parathyroid hormone-related protein (PTHrP) was identified as one of the major causes of humoral hypercalcemia of malignancy in several species. The hormone probably has an important role in the physiology and pathophysiology of mammals and birds. Many endocrine, paracrine and autocrine functions are attributed to PTHrP. Parathormone shares the same receptor with PTHrP. This receptor was isolated in many tissues. PTHrP could be an important fetal growth factor. The influence of PTHrP on calcium homeostasis is presently the object of active research. PTHrP stimulates calcium transfer through the placenta and maintains a concentration gradient between the dam's blood and the fetus. The hormone is produced in large quantities in milk. However, its exact and principal function in lactation has not yet been determined. Among other effects, PTHrP might stimulate the secretion of calcium, phosphate and magnesium in milk and might foster the development of the mammary gland. A role of PTHrP in the pathogenesis of postparturient paresis in dairy cows has been hypothesized. Results of recent trials demonstrate that despite an important role in calcium homeostasis, PTHrP is not pivotal in the development of milk fever.
 ...
PMID:[Parathyroid hormone related-protein and calcium homeostasis]. 766 95

The percutaneous ethanol injection (PEI) with ultrasound guidance has been suggested for the treatment of patients with hyperparathyroidism who are on dialysis, with the aim of selectively treating the parathyroid glands with nodular hyperplasia. We present our experience in 25 patients with chronic renal failure followed during 13.4 +/- 10.6 months. A decrease in the levels of parathormone (PTH) (1,236.32 +/- 129.8 vs. 721.66 +/- 142.24 pg/ml), phosphatemia (6.16 +/- 0.35 vs. 4.93 +/- 0.36 mg/dl) and calcium-phosphorous product (60.82 +/- 3.81 vs. 46.47 +/- 3.46 mg2/dl2) was verified. In 56% of patients, PTH levels decreased (>50% of the baseline value) and 36% had final values <300 pg/ml. Patients in whom ultrasound showed a single gland responded better than those with more than one gland (83.3 vs. 30.8% of responders in each group). The procedures performed had a 4.9% complication rate: hematoma, symptomatic hypocalcemia, temporary paresis of the vocal cords. In summary, treatment with PEI is useful for the management of patients with hyperparathyroidism who are on dialysis, and the results achieved are better in patients who have a single gland identified by ultrasonography.
 ...
PMID:Treatment of uremic hyperparathyroidism with percutaneous ethanol injection. 1594 51